Passive transfer of local immunity to influenza virus infection by IgA antibody
- PMID: 2005388
Passive transfer of local immunity to influenza virus infection by IgA antibody
Abstract
Secretory IgA is presumed to be the mediator of mucosal immunity based on many studies that show a correlation between protection and secretory IgA titers; however, a causal relationship has not yet been established. Classically, passive transfer of antibody has been used to demonstrate causality, but the passive transfer of local immunity with physiologically transported IgA has not been previously reported. In this study mice were injected intravenously with polymeric IgA (pIgA), monomeric IgA (mIgA), or IgG1 mAb specific for the H1 hemaglutinin of PR8 influenza virus. pIgA was shown to be specifically transported into nasal secretions relative to the mIg. The transported pIgA was functional, as evidenced by its ability to bind to virus in an ELISA assay and to protect nonimmune mice against intranasal infection with H1N1 but not H3N2 influenza virus. Intravenous injection of similar virus-neutralizing doses of anti-influenza IgG1 mAb did not protect against nasal viral challenge. IgA-mediated protection could be abrogated by the intranasal administration of antiserum against the alpha chain of IgA. These data demonstrate the passive transfer of local immunity by the i.v. administration of pIgA antibody and show that the IgA in secretions can protect against influenza virus infection. This general approach could provide a model for the evaluation of the role of local IgA in host defense against other pathogens.
Similar articles
-
Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules.Eur J Immunol. 1991 Jun;21(6):1337-44. doi: 10.1002/eji.1830210602. Eur J Immunol. 1991. PMID: 1646112
-
In vitro comparison of the biologic activities of monoclonal monomeric IgA, polymeric IgA, and secretory IgA.J Immunol. 1998 Feb 1;160(3):1219-23. J Immunol. 1998. PMID: 9570537
-
Mucosal immunity to influenza without IgA: an IgA knockout mouse model.J Immunol. 1999 Mar 1;162(5):2530-7. J Immunol. 1999. PMID: 10072492
-
Influenza: pathogenesis and host defense.Semin Respir Infect. 1992 Mar;7(1):38-45. Semin Respir Infect. 1992. PMID: 1609166 Review.
-
Defense mechanisms against influenza virus infection in the respiratory tract mucosa.Jpn J Infect Dis. 2004 Dec;57(6):236-47. Jpn J Infect Dis. 2004. PMID: 15623947 Review.
Cited by
-
Evaluation of events occurring at mucosal surfaces: techniques used to collect and analyze mucosal secretions and cells.Clin Diagn Lab Immunol. 2002 Jul;9(4):753-62. doi: 10.1128/cdli.9.4.753-762.2002. Clin Diagn Lab Immunol. 2002. PMID: 12093669 Free PMC article. Review. No abstract available.
-
Immunoglobulin A (IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization.Infect Immun. 2001 Apr;69(4):2328-38. doi: 10.1128/IAI.69.4.2328-2338.2001. Infect Immun. 2001. PMID: 11254590 Free PMC article.
-
Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA.Sci Immunol. 2021 Dec 10;6(66):eabj5129. doi: 10.1126/sciimmunol.abj5129. Epub 2021 Dec 10. Sci Immunol. 2021. PMID: 34890255 Free PMC article.
-
Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination.Infect Immun. 1998 Dec;66(12):5889-96. doi: 10.1128/IAI.66.12.5889-5896.1998. Infect Immun. 1998. PMID: 9826370 Free PMC article.
-
Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine.Infect Immun. 1998 Feb;66(2):823-6. doi: 10.1128/IAI.66.2.823-826.1998. Infect Immun. 1998. PMID: 9453648 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous